Leo Pharma Collaborates with PellePharm for the Development of Drug Candidate for Gorlin Syndrome and Basal Cell Carcinoma (BCC)
Shots:
- Leo Pharma to invest $70M as equity investment in Pelle with R&D support to initiate P-III trial for Patidegib globally. Leo Pharma has an option to acquire Pelle- in all stock transaction
- If Leo exercises its option Pelle to receive $690M as total deal value with milestones and royalties on sales. The P-III trial for Patidegib is expected to initiate in Q1’19
- Patidegib is a topical gel- received FDA’s Breakthrough Therapy & Orphan Drug Designation- for the treatment of Gorlin Syndrome
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
